LF-0376

N/A

Report date: 2024/04/18 16:34:32
NME

Base Information

Drug NameLF-0376
Drug Alias NameLF-0376
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionC-C chemokine receptor type 2 modulatorsC-C chemokine receptor type 5 modulators
TargetsC-C chemokine receptor type 2C-C chemokine receptor type 5
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsLiver Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuxi Hillhouse biomedicine Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesWuxi Hillhouse biomedicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsLiver Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A